Nasdaq Beater
Feed Explorer$Novo Nordisk AS(NVO.US) shared several views: First, the patent for semaglutide in the US expires in 2032. Second, only Novo Nordisk can legally sell its products in the US when there is no shortage of branded drugs. Third, the production process of oral semaglutide has strong barriers, and even if some companies produce generic drugs, their safety and efficacy are difficult to guarantee.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
